The UNC Breast Cancer SPORE's Developmental Research Program (DRP) promotes novel translational breast cancer research. The Program includes mechanisms for stimulating grant applications, evaluating and selecting projects, and monitoring progress. Drs. Lisa Carey, SPORE investigator and Medical Director of the UNC Breast Center, and Al Baldwin, SPORE investigator and UNC Lineberger Associate Director of Basic Science, oversee the DRP mechanisms for application, evaluation/selection, and monitoring. Application mechanisms include intra SPORE collaborations, Cancer Center-wide competitive-awards, and rapidly emerging opportunities. Evaluation and selection processes include independent peer review and consultation with SPORE senior leadership, external advisors, and advocates. The SPORE Director/Pi (Dr. Earp) and Co-Director/Co-Pi (Perou) make the final decisions regarding selection and budget. This DRP has been successful and effective. Since its inception in 1992, the UNC Breast Cancer SPORE has funded 42 projects. DRP projects have led to full-fledged SPORE projects and independently funded projects as well as publications. This report focuses primarily on outcomes from the most recent five years (Projects 30 - 42). During Years 15-19, UNC will commit $200,000 annually to developmental clinical, translational breast cancer research projects. We request $100,000 in SPORE funds to combine with $100,000 in institutional commitment to fund approximately three to five projects per year at $25,000 to $75,000/year. Funds for institutional commitment come primarily from the Cancer Center's Breast Cancer Research fundraising efforts. In Year 15 the program has identified two major projects for funding and will use established SPORE mechanisms, including the semi-annual competitive process, to make additional awards.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-16
Application #
7663917
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
16
Fiscal Year
2008
Total Cost
$141,368
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
McRee, Autumn J; Marcom, Paul K; Moore, Dominic T et al. (2018) A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. Clin Breast Cancer 18:289-297
DeBono, Nathan L; Robinson, Whitney R; Lund, Jennifer L et al. (2018) Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study. J Womens Health (Larchmt) 27:377-386
Nasarre, Patrick; Bonilla, Ingrid V; Metcalf, John S et al. (2018) TRAF3-interacting protein 3, a new oncotarget, promotes tumor growth in melanoma. Melanoma Res 28:185-194
Pearce, Oliver M T; Delaine-Smith, Robin M; Maniati, Eleni et al. (2018) Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. Cancer Discov 8:304-319
Williams, Lindsay A; Nichols, Hazel B; Hoadley, Katherine A et al. (2018) Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. Cancer Causes Control 29:25-32
Couture, Heather D; Williams, Lindsay A; Geradts, Joseph et al. (2018) Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype. NPJ Breast Cancer 4:30
Lei, Jonathan T; Shao, Jieya; Zhang, Jin et al. (2018) Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep 24:1434-1444.e7
Troester, Melissa A; Sun, Xuezheng; Allott, Emma H et al. (2018) Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst 110:
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12

Showing the most recent 10 out of 598 publications